Biotechnology companies traditionally received most of their financing for research and development and marketing from venture capitalists and private equity sources. The remainder usually was raised through public offerings, private investments in public entities, strategic alliances and governmental grants.
Unfortunately, the availability of capital for development-stage biotech companies has been diminished by the time, cost and risk of product development; by unexpected delays and failures in clinical or field trials; by uncertainties in regulatory approval; by the consolidation of big pharmaceutical companies; and by the phenomenal growth of Internet companies. Biotech companies, however, still can use their intellectual property portfolios to leverage financing opportunities.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
